Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.66 (market cap $7.77B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| PDBC | XBI | |
|---|---|---|
Market Cap | $7.77B | $10.11B |
Volume | 6,100,303 | 12,903,266 |
52-Week High | $20.10 | $169.55 |
52-Week Low | $13.16 | $104.99 |
Typical Hold Time | 56 Days | 38 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy ETF, trades at $19.65, up 1.24% with a bullish technical signal from moving averages. The fund has delivered strong performance, rising 45.66% year-to-date through Q3 2026, driven by energy and agricultural commodity gains amid geopolitical tensions. Institutional interest is growing with multiple firms increasing positions, though short interest surged 215.4% in September, indicating some bearish sentiment.
The outlook remains positive given ongoing commodity strength and defensive positioning, but risks include geopolitical volatility and potential commodity price corrections. The fund offers exposure to broad commodities as investors shift away from concentrated tech sectors, though elevated short interest suggests near-term volatility.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
